ArticleThe Korean journal of internal medicine2014

Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?

Seung-Ki KwokPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.